Generated by AI
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform. The company combines RNA interference with gene therapy to create treatments designed to silence disease-causing genes while also delivering functional gene replacement in a single administration. Its current work centers on ddRNAi-based therapeutics for chronic and life-threatening conditions, with a particular emphasis on rare genetic disorders such as oculopharyngeal muscular dystrophy. Benitec Biopharma’s pipeline reflects a precision medicine approach aimed at addressing unmet needs in genetic disease through targeted, durable molecular intervention. Headquartered in Hayward, California, Benitec Biopharma Inc. operates in the biotechnology and gene therapy sectors, where it contributes to the development of advanced platform-based therapies for difficult-to-treat human diseases.
Website3940 Trust Way
Hayward, CA, 94545
United States
The latest articles about BNTC.
Summary of Mar 9's posts. Generated by AI.
Summary of Apr 18's posts. Generated by AI.
Summary of Apr 18's posts. Generated by AI.
Summary of Apr 18's posts. Generated by AI.
Investors talking about BNTC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.